Woodline Partners’s Arcus Biosciences RCUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$81.6M Buy
3,777,798
+8,010
+0.2% +$173K 0.31% 61
2025
Q4
$89.8M Buy
3,769,788
+104
+0% +$2.12K 0.35% 57
2025
Q3
$51.3M Sell
3,769,684
-230,345
-6% -$2.4M 0.24% 108
2025
Q2
$32.6M Sell
4,000,029
-1,127,275
-22% -$9.63M 0.17% 168
2025
Q1
$40.2M Buy
5,127,304
+1,603,367
+45% +$18.6M 0.26% 116
2024
Q4
$52.5M Buy
3,523,937
+45,497
+1% +$743K 0.35% 72
2024
Q3
$53.2M Sell
3,478,440
-766,781
-18% -$12.1M 0.45% 57
2024
Q2
$64.7M Buy
4,245,221
+1,361,564
+47% +$22M 0.62% 37
2024
Q1
$54.4M Buy
2,883,657
+1,846,375
+178% +$31.9M 0.5% 52
2023
Q4
$19.8M Hold
1,037,282
0.22% 143
2023
Q3
$18.6M Buy
1,037,282
+789,282
+318% +$15.9M 0.22% 141
2023
Q2
$5.04M Buy
+248,000
New +$4.72M 0.06% 289
2023
Q1
Sell
-1,201,150
Closed -$24.8M 758
2022
Q4
$24.8M Buy
+1,201,150
New +$33.1M 0.33% 80
2022
Q2
Sell
-261,419
Closed -$8.25M 872
2022
Q1
$8.25M Sell
261,419
-1,445,006
-85% -$48.4M 0.13% 190
2021
Q4
$69.1M Buy
1,706,425
+7,312
+0.4% +$284K 0.99% 15
2021
Q3
$59.2M Buy
1,699,113
+35,545
+2% +$1.11M 0.97% 20
2021
Q2
$45.7M Buy
1,663,568
+425,838
+34% +$12.2M 0.85% 23
2021
Q1
$34.8M Buy
+1,237,730
New +$43.1M 0.77% 34
2020
Q2
Sell
-98,516
Closed -$1.37M 180
2020
Q1
$1.37M Buy
+98,516
New +$1.23M 0.1% 122

Other funds holding RCUS

Woodline Partners's RCUS Position: Q1 2026 in Review

Woodline Partners increased its Arcus Biosciences (RCUS) stake by 0.21% in Q1 2026, buying an estimated $173K and bringing the position to 3,777,798 shares worth $81.6M. The position accounts for 0.31% of the portfolio, ranked #61.

Woodline Partners first reported a position in RCUS in Q1 2020 and has held it in 19 quarters since. The position peaked at $89.8M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Woodline Partners held 3,777,798 shares of Arcus Biosciences worth $81.6M as of Q1 2026.
  • Woodline Partners bought 8,010 Arcus Biosciences shares in Q1 2026, an estimated $173K.
  • Arcus Biosciences made up 0.31% of Woodline Partners's portfolio in Q1 2026, its #61 holding.
  • Woodline Partners first reported a position in Arcus Biosciences in Q1 2020 and has held it in 19 quarters since.
  • Woodline Partners's Arcus Biosciences position peaked at $89.8M in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.